相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Plasma and cerebrospinal fluid pharmacokinetics of valproic acid after oral administration in non-human primates
Stacie L. Stapleton et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2008)
Dietary histone deacetylase inhibitors: From cells to mice to man
Roderick H. Dashwood et al.
SEMINARS IN CANCER BIOLOGY (2007)
Chronic administration of valproic acid inhibits PC3 cell growth by suppressing tumor angiogenesis in vivo
Dexuan Gao et al.
INTERNATIONAL JOURNAL OF UROLOGY (2007)
Valproic acid (VPA) in patients with refractory advanced cancer:: a dose escalating phase I clinical trial
A. Atmaca et al.
BRITISH JOURNAL OF CANCER (2007)
Multiple molecular pathways explain the anti-proliferative effect of valproic acid on prostate cancer cells InVitro and InVivo
Shabana Shabbeer et al.
PROSTATE (2007)
Valproic acid inhibits adhesion of vincristine- and cisplatin-resistant neuroblastoma tumour cells to endothelium
R. A. Blaheta et al.
BRITISH JOURNAL OF CANCER (2007)
Phase I trial of histone deacetylase inhibition by valproic acid followed by the topoisomerase II inhibitor epirubicin in advanced solid tumors:: A clinical and translational study
Pamela Muenster et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Modulation of angiogenesis by dithiolethione-modified NSAIDs and valproic acid
J. S. Isenberg et al.
BRITISH JOURNAL OF PHARMACOLOGY (2007)
Valproic acid-induced hepatopathy:: Nine new fatalities in Germany from 1994 to 2003
Stephan A. Koenig et al.
EPILEPSIA (2006)
Valproic acid induces apoptosis in prostate carcinoma cell lines by activation of multiple death pathways
Adriano Angelucci et al.
ANTI-CANCER DRUGS (2006)
Peroxisome proliferator-activated receptor γ regulates E-cadherin expression and inhibits growth and invasion of prostate cancer
Jean-Sebastien Annicotte et al.
MOLECULAR AND CELLULAR BIOLOGY (2006)
Chronic administration of valproic acid inhibits prostate cancer cell growth in vitro and in vivo
Qinghua Xia et al.
CANCER RESEARCH (2006)
Prostate tumor CXC-chemokine profile correlates with cell adhesion to endothelium and extracellular matrix
T Engl et al.
LIFE SCIENCES (2006)
Teratogenic effects mediated by inhibition of histone deacetylases: Evidence from quantitative structure activity relationships of 20 valproic acid derivatives
D Eikel et al.
CHEMICAL RESEARCH IN TOXICOLOGY (2006)
Histone deacetylases inhibition and tumor cells cytotoxicity by CNS-active VPA constitutional isomers and derivatives
S Eyal et al.
BIOCHEMICAL PHARMACOLOGY (2005)
Valproic acid modulates NCAM polysialylation and polysialyltransferase mRNA expression in human tumor cells
WD Beecken et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2005)
Upregulation and nuclear recruitment of HDACI in hormone refractory prostate cancer
K Halkidou et al.
PROSTATE (2004)
Valproic acid inhibits angiogenesis in vitro and in vivo
M Michaelis et al.
MOLECULAR PHARMACOLOGY (2004)
Zn2+-chelating motif-tethered short-chain fatty acids as a novel class of histone deacetylase inhibitors
Q Lu et al.
JOURNAL OF MEDICINAL CHEMISTRY (2004)
Anti-tumor mechanisms of valproate: A novel role for an old drug
RA Blaheta et al.
MEDICINAL RESEARCH REVIEWS (2002)
Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells
M Göttlicher et al.
EMBO JOURNAL (2001)
Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen
CJ Phiel et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
Induction of histone acetylation in mouse erythroleukemia cells by some organosulfur compounds including allyl isothiocyanate
MA Lea et al.
INTERNATIONAL JOURNAL OF CANCER (2001)
分享论文
